1400 related articles for article (PubMed ID: 27397505)
1. A Landscape of Pharmacogenomic Interactions in Cancer.
Iorio F; Knijnenburg TA; Vis DJ; Bignell GR; Menden MP; Schubert M; Aben N; Gonçalves E; Barthorpe S; Lightfoot H; Cokelaer T; Greninger P; van Dyk E; Chang H; de Silva H; Heyn H; Deng X; Egan RK; Liu Q; Mironenko T; Mitropoulos X; Richardson L; Wang J; Zhang T; Moran S; Sayols S; Soleimani M; Tamborero D; Lopez-Bigas N; Ross-Macdonald P; Esteller M; Gray NS; Haber DA; Stratton MR; Benes CH; Wessels LFA; Saez-Rodriguez J; McDermott U; Garnett MJ
Cell; 2016 Jul; 166(3):740-754. PubMed ID: 27397505
[TBL] [Abstract][Full Text] [Related]
2. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.
Pavel AB; Sonkin D; Reddy A
BMC Syst Biol; 2016 Feb; 10():16. PubMed ID: 26864072
[TBL] [Abstract][Full Text] [Related]
3. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
[TBL] [Abstract][Full Text] [Related]
5. Explainable drug sensitivity prediction through cancer pathway enrichment.
Tang YC; Gottlieb A
Sci Rep; 2021 Feb; 11(1):3128. PubMed ID: 33542382
[TBL] [Abstract][Full Text] [Related]
6. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
7. Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines.
Krushkal J; Vural S; Jensen TL; Wright G; Zhao Y
Clin Epigenetics; 2022 Dec; 14(1):161. PubMed ID: 36461044
[TBL] [Abstract][Full Text] [Related]
8. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
9. Genetic load makes cancer cells more sensitive to common drugs: evidence from Cancer Cell Line Encyclopedia.
Pavel AB; Korolev KS
Sci Rep; 2017 May; 7(1):1938. PubMed ID: 28512298
[TBL] [Abstract][Full Text] [Related]
10. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data.
Xu Y; Dong Q; Li F; Xu Y; Hu C; Wang J; Shang D; Zheng X; Yang H; Zhang C; Shao M; Meng M; Xiong Z; Li X; Zhang Y
J Transl Med; 2019 Aug; 17(1):255. PubMed ID: 31387579
[TBL] [Abstract][Full Text] [Related]
11. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.
Pozdeyev N; Yoo M; Mackie R; Schweppe RE; Tan AC; Haugen BR
Oncotarget; 2016 Aug; 7(32):51619-51625. PubMed ID: 27322211
[TBL] [Abstract][Full Text] [Related]
12. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
13. DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration.
Wang Y; Yang Y; Chen S; Wang J
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33822890
[TBL] [Abstract][Full Text] [Related]
14. RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance.
Choi J; Park S; Ahn J
Sci Rep; 2020 Feb; 10(1):1861. PubMed ID: 32024872
[TBL] [Abstract][Full Text] [Related]
15. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.
Seashore-Ludlow B; Rees MG; Cheah JH; Cokol M; Price EV; Coletti ME; Jones V; Bodycombe NE; Soule CK; Gould J; Alexander B; Li A; Montgomery P; Wawer MJ; Kuru N; Kotz JD; Hon CS; Munoz B; Liefeld T; Dančík V; Bittker JA; Palmer M; Bradner JE; Shamji AF; Clemons PA; Schreiber SL
Cancer Discov; 2015 Nov; 5(11):1210-23. PubMed ID: 26482930
[TBL] [Abstract][Full Text] [Related]
16. PLATYPUS: A Multiple-View Learning Predictive Framework for Cancer Drug Sensitivity Prediction.
Graim K; Friedl V; Houlahan KE; Stuart JM
Pac Symp Biocomput; 2019; 24():136-147. PubMed ID: 30864317
[TBL] [Abstract][Full Text] [Related]
17. Link synthetic lethality to drug sensitivity of cancer cells.
Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
[TBL] [Abstract][Full Text] [Related]
18. Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.
Ree AH; Nygaard V; Boye K; Heinrich D; Dueland S; Bergheim IR; Johansen C; Beiske K; Negård A; Lund-Iversen M; Nygaard V; Hovig E; Nakken S; Nasser S; Julsrud L; Reisse CH; Ruud EA; Kristensen VN; Flørenes VA; Geitvik GA; Lingjærde OC; Børresen-Dale AL; Russnes HG; Mælandsmo GM; Flatmark K
Acta Oncol; 2020 Jul; 59(7):733-740. PubMed ID: 32208873
[No Abstract] [Full Text] [Related]
19. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
[TBL] [Abstract][Full Text] [Related]
20. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Shee K; Wells JD; Jiang A; Miller TW
PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
